Exponent, Inc. — Form 10-Q Summary
Reporting period: Quarter ended September 29, 2023; comparative periods ended September 30, 2022. The request metadata says “2022 Q3,” but the supplied filing is for 2023 Q3.
Business context and results
Exponent provides multidisciplinary engineering and scientific consulting. Its two segments are Engineering and Other Scientific, and Environmental and Health. Amounts below are in millions except per-share data.
| Metric | Q3 2023 | Q3 2022 | First 9 months 2023 | First 9 months 2022 |
|---|---|---|---|---|
| Revenue | $133.3 | $127.2 | $413.9 | $385.9 |
| Revenue before reimbursements | $125.0 | $115.1 | $383.3 | $351.2 |
| Operating income | $33.9 | $36.8 | $92.9 | $118.8 |
| Net income | $24.5 | $24.4 | $79.4 | $79.8 |
| Diluted EPS | $0.48 | $0.47 | $1.54 | $1.52 |
| EBITDA margin on revenue before reimbursements | 27.6% | 30.0% | 27.9% | 30.2% |
Q3 revenue rose 4.8% (9% before reimbursements); nine-month revenue rose 7.2%. Growth reflected higher billable hours and billing rates, with demand across transportation, energy, construction, and chemical regulatory consulting. Q3 Engineering and Other Scientific revenue grew 3.2%; Environmental and Health grew 13.7%.
Profitability, cash flow and liquidity
- Operating income fell 7.8% in Q3 and 21.8% for the first nine months, despite revenue growth. Compensation and related expenses rose 17.9% in Q3 and 26.9% year to date, reflecting increased staffing, pay and benefits, stock compensation, and deferred-compensation effects. Corporate operating expense also increased substantially year to date.
- Utilization declined to 70% in Q3 from 73% a year earlier; technical full-time equivalent employees increased 10% to 1,050. Management attributed lower utilization in part to rapid hiring.
- Nine-month operating cash flow was $56.0 million, versus $53.2 million. Capital expenditures were $14.4 million versus $9.1 million; financing cash outflow was $66.0 million, including $40.9 million of dividends and $17.0 million of share repurchases.
- Cash and cash equivalents were $137.1 million at September 29, 2023, down from $161.5 million at December 30, 2022. Current assets were $343.3 million and current liabilities $129.7 million. The balance sheet reports no borrowings or other debt.
- Dividends declared were $0.26 per share for Q3 and $0.78 per share year to date. The board also declared a $0.26-per-share dividend payable December 22, 2023.
Outlook, risks and unusual items
- No numerical revenue or earnings guidance is provided. Management said cash, cash generated from operations, and cash equivalents should cover working capital, capital expenditures, commitments, repurchases, dividends, and other liquidity needs for at least the next 12 months.
- Management expects other operating expenses to grow with infrastructure investment, and G&A expenses to increase with business-development and staff-development initiatives. It cited continued moderation in consumer electronics work, partly offset by demand in other areas.
- A client sought a $2 million concession related to project performance. Exponent disputes the request; management said it believes the matter is unlikely to have a material adverse effect, but the outcome is uncertain. The filing reports no material legal proceedings.
- Key stated risks include changes in economic and industry conditions, engagement timing, competition and pricing, ability to attract and retain employees, regulatory and tort developments, claims, and foreign-exchange movements. The company does not hedge foreign-currency exposure.
- Deferred-compensation plan assets and liabilities are subject to market-value changes; the plan is held in a rabbi trust subject to creditors’ claims. The filing also describes a $2.2 million nine-month net effect from plan-asset market changes on compensation and other income, with offsetting presentation across those lines.
Important facts for investors to verify
- Confirm the intended reporting period: the supplied filing is 2023 Q3, not 2022 Q3.
- Track whether utilization recovers as recently expanded technical staffing is deployed, and whether revenue growth translates into operating-profit growth.
- Review the timing and collectability of receivables, and the effect of declining deferred revenue on future billings and cash flow.
- Monitor the disputed client concession and deferred-compensation plan asset/liability exposure.
- Verify capital-allocation levels: the repurchase program had approximately $45.6 million remaining at quarter-end; the filing states management may also use cash for dividends or complementary acquisitions.